Dangerous Drug: Carboplatin(kar’ boe pla tin)
PREGNANCY CATEGORY D
Drug Classes
Alkylating drug
Antineoplastic
Therapeutic Actions
Cytotoxic: Heavy metal that produces cross-links within and between strands of DNA, thus preventing cell replication; cell cycle nonspecific.
Indications
Initial treatment of advanced ovarian carcinoma in combination with other antineoplastics
Palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been treated with cisplatin
Unlabeled uses: Alone or with other agents to treat small-cell lung cancer, squamous cell cancer of the head and neck, endometrial cancer, relapsed or refractory acute leukemia, seminoma of testicular cancer
Contraindications and Cautions
Contraindicated with history of severe allergic reactions to carboplatin, cisplatin, platinum compounds, mannitol; severe bone marrow depression; lactation.
Use cautiously in renal impairment, pregnancy, history of neuropathic disorders.
Available Forms
Powder for injection—150 mg; injection—10 mg/mL
Dosages
Adults
As a single agent: 360 mg/m2 IV on day 1 every 4 wk. Do not repeat single doses of carboplatin until the neutrophil count is at least 2,000/mm3 and the platelet count is at least 100,000/mm3. These adjustments of dosage can be used: For platelets more than 100,000 and neutrophils more than 2,000, use dosage 125% of prior course; for platelets 50,000–100,000 and neutrophils 500–2,000, no adjustment in dosage; for platelets less than 50,000 and neutrophils less than 500—dosage 75% of previous course. Doses of more than 125% are not recommended. May also be given at 300 mg/m2 in combination with cyclophosphamide.
Pediatric patients
Safety and efficacy not established.
Geriatric patients and patients with renal impairment
Increased risk of bone marrow depression with renal impairment. Use caution.
|
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
